Praxis Precision Medicines, Inc. PRAX Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
- Praxis Precision Medicines, Inc. (PRAX) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number of $1.95M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number changed year-over-year?
- Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number decreased by 5.1% year-over-year, from $2.05M to $1.95M.